UPDATE: Goldman Sachs Reiterates Buy Rating, Lowers PT on McKesson Corporation Following ABC/WAG Deal

Loading...
Loading...
In a report published Wednesday, Goldman Sachs analyst Robert P. Jones reiterated a Buy rating on McKesson Corporation
MCK
, but lowered the price target from $124.00 to $122.00. In the report, Jones noted, “On our new estimates, ABC now trades at a 2x P/E multiple premium to MCK and CAH. While some may argue that ABC's valuation is justifiable given growth and support to numbers from the announced WAG deal, we find it difficult to overcome at current levels and maintain our Neutral rating. We still see the greatest risk/reward in MCK trading essentially at parity with CAH on our CY14, given (1) a more attractive growth profile through CY2014 after CAH's loss of WAG, (2) pending CVS contract renewals, which pose a risk for both, but greater for CAH at 31% of sales, versus MCK at 16%, and (3) a more attractive Specialty footprint - a differentiator in outer years.” McKesson Corporation closed on Tuesday at $106.87.
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsGoldman SachsHealth CareHealth Care Distributors
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...